RxDoctor Payments Data

Alivia Hoeltke

Family · Columbus, INNPI 1154104180

Payments from drug & device makers

$1,467in general payments, 2019–2025

Across 42 payments — averaging $34.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$638
  • AstraZeneca$222
  • Fresenius USA Marketing, Inc.$126
  • Bayer$124
  • Stryker$99
  • Boston Scientific$86
  • plus $172 from 5 others

What the payments were for

  • Food & beverage$1,44799%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,467 in reported general payments places this provider in the 70th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$27,705
Medicare patients
149
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol19$29,299
Torsemide85$1,665
Sevelamer Carbonate20$1,581
Doxazosin Mesylate25$478
Spironolactone32$358
Metoprolol Succinate19$338
Amlodipine Besylate60$309
Losartan Potassium56$285
Hydralazine Hcl31$279
Lisinopril63$226
Potassium Chloride13$200
Valsartan15$182
Furosemide32$160
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$137
Clonidine Hcl12$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$222$29,29919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,392 family providers in Indiana.

Other family in Columbus

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →